Human Umbilical Cord Blood Infusion in Patients With Cerebral Palsy - Trial NCT06377982
Access comprehensive clinical trial information for NCT06377982 through Pure Global AI's free database. This Phase 1 trial is sponsored by StemCyte Taiwan Co., Ltd. and is currently Not yet recruiting. The study focuses on Cerebral Palsy. Target enrollment is 12 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
StemCyte Taiwan Co., Ltd.
StemCyte International, Ltd.
Timeline & Enrollment
Phase 1
Sep 01, 2024
Dec 01, 2026
Primary Outcome
safety-TEAE
Summary
A phase I, randomized, double-blind, placebo-controlled clinical study to assess the safety
 and efficacy of allogeneic human umbilical cord blood infusion in children with cerebral
 palsy
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06377982
Non-Device Trial